loading...
Dimension not matched!

D e l i v e r   H o p e   f o r   a   B e t t e r   L i f e

Milestones

2024

  • 05 Capital injection for NT$ 964,903,710 and exercise of employee stock options for NT$194,700 respectively
  • 03 The stock was officially listed on the Securities TPEx Trading Center.

2023

  • 12 US FDA has granted orphan drug designation to L608 for the treatment of Systemic Sclerosis (SSc)
  • 12 The Ministry of Economic Affairs has approved and issued a letter for the biotechnology new drug investment project "L608," allowing shareholders to benefit from tax deductions under the Biotechnology and New Pharmaceuticals Industry Development Act.
  • 11 Exercise of employee stock options for NT$2,204,000
  • 09 Capital injection for NT$360,000,000
  • 08 L608 (liposomal-iloprost), obtained the approval of the Australian HREC to conduct the Phase I clinical trial, and has been acknowledged by the Australian TGA for Clinical Trial Notification (CTN).
  • 07 Exercise of employee stock options for NT$2,253,900
  • 06 Pharmosa announced the collaboration with Liquidia Technologies, Inc. For L606 in North America
  • 03 L606 submitted the Phase 3 study protocol amendment to the US FDA to expand the enrolled patient population

2022

  • 12 Capital injection for NT$494,000,000 and exercise of employee stock options for NT$1,419,000 respectively
  • 02 Successfully enlisted in Emgerging Market; Stock Code: 6875

2021

  • 11 Obtained approval for Public Status Registration with Securities and Futures Bureau, Financial Supervisory Commission; Stock Code: 6875
  • 10 Capital injection for NT$300,000,000 and exercise of employee stock options for NT$66,040,000 respectively
  • 08 L606 launched phase III pivotal trial in US
  • 01 Capital injection for NT$486,978,000

2020

  • 12 L606 FDA submission for Phase III pivotal trial
  • 05 Issuance of new restricted employee shares for NT 5,000,000.
  • 04 Capital injection of NT$150,000,000

2019

  • 10 L606 received subsidies from the "A+ Industrial Innovative R&D Program - Fast Track Clinical Trial Program" sponsored by MOEA.
  • 09 L606 received last patient in for phase I clinical trial
  • 07 Changed face value to NT$5 per share (face value was originally at NT$10 per share)
  • 05 Capital injection of NT$25,000,000
  • 04 L606 received first patient in for phase I clinical trial
  • 04 Capital injection of NT$25,000,000
  • 03 L606 launched Phase I clinical trial in US
  • 01 L606 received FDA approval for Phase I study

2018

  • 12 Received qualifying status for our investors to receive Tax Incentive from investment per the “Act For The Development of Biotech And New Pharmaceuticals Industry” governed by MOEA, R.O.C.
  • 09 Capital injection for NT$50,000,000
  • 05 Submission of USPTO provisional application (application No.: 62667889 and 62670875)

2017

  • 10 Received Government grant funded by MOEA
  • 07 Submission of USPTO provisional application (application No.: 62536034 and 62595207)

2016

  • 10 Renamed company to “國邑藥品科技股份有限公司” in Chinese & “Pharmosa Biopharm Inc.” in English
  • 10 Re-locating headquarter from Taichung to Nangang Software Park III, Nangang District, Taipei City
  • 05 Focusing on new drug development through the 505(b)2 pathway

1990~2015

Pharmosa Limited (a predecessor of Pharmosa Biopharm Inc.)

  • Recognized as a "Biotech and New Pharmaceutical Company" by the Act For The Development of Biotech And New Pharmaceuticals Industry, governed by Ministry of Economic Affairs (MOEA), R.O.C.
  • Licensing various Gx Products to Anxo Pharma
  • M480384 patent granted in Taiwan and China
  • 2010, Setup of R&D Center in Nangang Software Park III, Nangang District, Taipei City
  • 2000, Pharmosa Limited founded in Taichung.